Astrazeneca PLC AZN
Astrazeneca PLC (NYSE: AZN) is an oncology drug developer. Its lead program, Marketed portfolio (e.g., Farxiga, Tagrisso, Imfinzi, Enhertu), is in Phase 3 for oncology, CVRM, respiratory & immunology, rare disease. Its next catalyst on record is Imfinzi +/- oleclumab +/- monalizumab PACIFIC-9: Phase III data readout (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Imfinzi +/- oleclumab +/- monalizumab PACIFIC-9 — Phase III data readout (H2 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Tagrisso (osimertinib) | EGFRm NSCLC | small molecule | Approved |
| Farxiga/Forxiga (dapagliflozin) | T2D, heart failure, CKD | small molecule | Approved |
| Imfinzi (durvalumab) | multiple cancers (NSCLC, SCLC, BTC, HCC, bladder, gastric, endometrial) | antibody | Approved |
| Enhertu (trastuzumab deruxtecan; partnered) | HER2+ breast, gastric, NSCLC, tumour-agnostic | antibody | Approved |
| Calquence (acalabrutinib) | CLL, MCL | small molecule | Approved |
| Lynparza (olaparib; partnered) | ovarian, breast, pancreatic, prostate cancers | small molecule | Approved |
| Fasenra (benralizumab) | severe eosinophilic asthma, EGPA | antibody | Approved |
| Brilinta/Brilique (ticagrelor) | ACS / MI | small molecule | Approved |
| Datroway (datopotamab deruxtecan; partnered) | HR+/HER2- breast cancer, EGFRm NSCLC | antibody | Approved |
| Saphnelo (anifrolumab) | systemic lupus erythematosus | antibody | Approved |
| camizestrant (SERENA-6 and SERENA-4) | HR+ HER2- breast cancer | small molecule | Phase 3 |
| baxdrostat (BaxHTN/Bax24/BaxAsia) | hypertension | small molecule | Phase 3 |
Recent results and decisions
- Oct 22, 2026approval Ultomiris received accelerated FDA approval as the first and only C5 complement inhibitor to reduce proteinuria in adults with primary IgAN.
Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy
Filing - Oct 22, 2026met I CAN Phase III trial prespecified interim analysis showed Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks.
Results showed Ultomiris demonstrated a 43.4% reduction in proteinuria vs placebo at 34 weeks.
Filing - Oct 22, 2026submitted Regulatory submissions based on I CAN trial interim results are under review in Japan and additional countries.
Regulatory submissions based on the interim results from the I CAN trial are also under review in Japan and additional countries.
Filing
77 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.